EG25924A - A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate - Google Patents

A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate

Info

Publication number: EG25924A
Authority: EG; Egypt
Prior art keywords: vaccine composition; adsorbed onto; aluminium phosphate; polysaccharide conjugate; onto aluminium
Prior art date: 1995-06-23

Application number

EG57496A

Other languages

English (en)

Inventor

Julien Peetermans

Pierre Hauser

Original Assignee

Smithkline Beecham Biolog

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-23

Filing date

1996-06-22

Publication date

2012-10-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451299&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG25924(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-23 Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en

1995-07-01 Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en

1995-12-15 Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en

1996-03-22 Priority claimed from GBGB9606032.2A external-priority patent/GB9606032D0/en

1996-06-22 Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog

2012-10-22 Application granted granted Critical

2012-10-22 Publication of EG25924A publication Critical patent/EG25924A/xx

Links

ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 title 1
229940001007 aluminium phosphate Drugs 0.000 title 1
229910000147 aluminium phosphate Inorganic materials 0.000 title 1
239000000427 antigen Substances 0.000 title 1
102000036639 antigens Human genes 0.000 title 1
108091007433 antigens Proteins 0.000 title 1
150000004676 glycans Chemical class 0.000 title 1
229920001282 polysaccharide Polymers 0.000 title 1
239000005017 polysaccharide Substances 0.000 title 1
229960005486 vaccine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Mycology (AREA)
Immunology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EG57496A 1995-06-23 1996-06-22 A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate EG25924A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB9512827.8A GB9512827D0 (en)	1995-06-23	1995-06-23	Vaccines
GBGB9513443.3A GB9513443D0 (en)	1995-07-01	1995-07-01	Vaccines
GBGB9525657.4A GB9525657D0 (en)	1995-12-15	1995-12-15	Vaccines
GBGB9606032.2A GB9606032D0 (en)	1996-03-22	1996-03-22	Vaccines

Publications (1)

Publication Number	Publication Date
EG25924A true EG25924A (en)	2012-10-22

Family

ID=27451299

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG57496A EG25924A (en)	1995-06-23	1996-06-22	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate

Country Status (36)

Country	Link
EP (2)	EP0833662B2 (xx)
JP (2)	JP4850987B2 (xx)
KR (1)	KR100425929B1 (xx)
CN (1)	CN1146444C (xx)
AP (1)	AP812A (xx)
AR (1)	AR003006A1 (xx)
AT (2)	ATE433329T1 (xx)
AU (1)	AU696338B2 (xx)
BG (1)	BG62720B1 (xx)
BR (1)	BRPI9609414B8 (xx)
CA (1)	CA2222455C (xx)
CY (1)	CY2297B1 (xx)
CZ (1)	CZ288908B6 (xx)
DE (2)	DE69612198T3 (xx)
DK (2)	DK0833662T4 (xx)
DZ (1)	DZ2055A1 (xx)
EA (1)	EA199700413A1 (xx)
EG (1)	EG25924A (xx)
ES (2)	ES2325301T3 (xx)
GR (1)	GR3036088T3 (xx)
HK (2)	HK1037516A1 (xx)
HU (1)	HU224514B1 (xx)
IL (1)	IL122588A (xx)
MA (1)	MA23918A1 (xx)
MY (1)	MY114786A (xx)
NO (1)	NO325169B1 (xx)
NZ (1)	NZ312132A (xx)
OA (1)	OA10646A (xx)
PE (1)	PE11298A1 (xx)
PL (1)	PL184872B1 (xx)
PT (2)	PT833662E (xx)
SI (2)	SI0833662T2 (xx)
SK (1)	SK176197A3 (xx)
TR (1)	TR199701682T1 (xx)
TW (1)	TW467746B (xx)
WO (1)	WO1997000697A1 (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK280702B6 (sk)	1992-05-23	2000-06-12	Smithkline Beecham Biologicals S. A.	Kombinovaný očkovací prostriedok obsahujúci povrch
US6355450B1 (en)	1995-04-21	2002-03-12	Human Genome Sciences, Inc.	Computer readable genomic sequence of Haemophilus influenzae Rd, fragments thereof, and uses thereof
US6468765B1 (en)	1995-04-21	2002-10-22	Human Genome Sciences, Inc.	Selected Haemophilus influenzae Rd polynucleotides and polypeptides
US6696065B1 (en)	1995-05-04	2004-02-24	Aventis Pastuer Limited	Acellular pertussis vaccines and methods of preparation thereof
ATE433329T1 (de) *	1995-06-23	2009-06-15	Glaxosmithkline Biolog Sa	Impfstoff bestehend aus auf aluminium-phosphat adsorbiertem, konjugiertem polysaccharid antigen
AU714493B2 (en) *	1996-07-02	2000-01-06	Connaught Laboratories Limited	Multivalent DTP-polio vaccines
GB9806456D0 (en) *	1998-03-25	1998-05-27	Smithkline Beecham Biolog	Vaccine composition
PL201482B1 (pl) *	1998-10-16	2009-04-30	Smithkline Beecham Biolog	Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
US6585973B1 (en) *	1998-10-29	2003-07-01	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Method for preparing solid phase conjugated vaccine
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
UA85853C2 (uk)	2000-06-29	2009-03-10	Глаксосмітклайн Байолоджікалз С.А.	Полівалентна імуногенна композиція
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
PL226184B1 (pl)	2001-01-23	2017-06-30	Aventis Pasteur	Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
SI1549338T1 (sl)	2002-10-11	2011-04-29	Novartis Vaccines & Diagnostic	Polipeptidna cepiva za ĺ iroko zaĺ äśito pred hipervirulentnimi miningokoknimi rodovi
AU2003278166B2 (en) *	2002-11-01	2009-01-29	Glaxosmithkline Biologicals S.A.	Immunogenic composition
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
CA2514328C (en)	2003-01-30	2020-01-14	Chiron Srl	Injectable vaccines against multiple meningococcal serogroups
GB0313916D0 (en)	2003-06-16	2003-07-23	Glaxosmithkline Biolog Sa	Vaccine composition
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
EP1961426B1 (en)	2003-10-02	2011-04-27	Novartis Vaccines and Diagnostics S.r.l.	Combined meningitis vaccines
US8574596B2 (en) *	2003-10-02	2013-11-05	Glaxosmithkline Biologicals, S.A.	Pertussis antigens and use thereof in vaccination
GB0405787D0 (en) *	2004-03-15	2004-04-21	Chiron Srl	Low dose vaccines
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
SI1740217T1 (sl)	2004-04-30	2011-10-28	Novartis Ag	Konjugirano meningokokno cepljenje
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0505518D0 (en)	2005-03-17	2005-04-27	Chiron Srl	Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en)	2005-03-23	2005-04-27	Glaxosmithkline Biolog Sa	Fermentation process
WO2006113528A2 (en)	2005-04-18	2006-10-26	Novartis Vaccines And Diagnostics Inc.	Expressing hepatitis b virus surface antigen for vaccine preparation
CN103083657B (zh)	2005-06-27	2016-06-08	葛兰素史密丝克莱恩生物有限公司	免疫原性组合物
GB0522765D0 (en)	2005-11-08	2005-12-14	Chiron Srl	Combination vaccine manufacture
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
US10828361B2 (en)	2006-03-22	2020-11-10	Glaxosmithkline Biologicals Sa	Regimens for immunisation with meningococcal conjugates
TR201807355T4 (tr)	2006-03-22	2018-06-21	Glaxosmithkline Biologicals Sa	Meningokokkal konjugatlarla immünizasyon rejimleri.
NZ575273A (en)	2006-09-07	2012-02-24	Glaxosmithkline Biolog Sa	Method for making combination vaccine comprising inactivated poliovirus type 1, diptheria toxoid and tetanus toxoid
US20100074918A1 (en)	2007-05-02	2010-03-25	Jan Poolman	Vaccine
NZ581367A (en)	2007-06-04	2012-05-25	Novartis Ag	Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis
FR2918671B1 (fr) *	2007-07-10	2010-10-15	Sanofi Pasteur	Milieu de culture d'haemophilus influenzae type b.
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0822633D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Formulation
TW201043267A (en) *	2009-03-19	2010-12-16	Intervet Int Bv	In situ constituting a vaccine for administration to a predetermined herd of animals
CN102427826B (zh) *	2009-03-24	2014-11-26	诺华股份有限公司	为脑膜炎球菌因子h结合蛋白添加佐剂
IT1398927B1 (it)	2009-06-25	2013-03-28	Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi	Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en)	2009-10-08	2009-11-25	Glaxosmithkline Biolog Sa	Expression system
CN103442730B (zh)	2011-01-05	2016-08-17	巴拉特生物技术国际有限公司	组合七价疫苗
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
GB2495341B (en)	2011-11-11	2013-09-18	Novartis Ag	Fermentation methods and their products
EP2592137A1 (en)	2011-11-11	2013-05-15	Novartis AG	Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011122891B4 (de)	2011-11-11	2014-12-24	Novartis Ag	Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de)	2011-11-11	2014-02-13	Novartis Ag	Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
JP6181082B2 (ja)	2012-02-01	2017-08-16	グラクソスミスクラインバイオロジカルズソシエテアノニム	発酵方法
WO2014009971A2 (en) *	2012-07-07	2014-01-16	Bharat Biotech International Limited	Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
AU2013301312A1 (en)	2012-08-06	2015-03-19	Glaxosmithkline Biologicals S.A.	Method for eliciting in infants an immune response against RSV and B. pertussis
MX2015004652A (es)	2012-10-12	2015-08-05	Glaxosmithkline Biolog Sa	Antigenos de pertusis acelulares no entrelazados para uso en vacunas de combinacion.
KR20160040290A (ko)	2013-08-05	2016-04-12	글락소스미스클라인 바이오로지칼즈 에스.에이.	조합 면역원성 조성물
US11219680B2 (en)	2017-02-24	2022-01-11	Merck Sharp & Dohme Corp.	Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier
SG11202000224SA (en)	2017-07-18	2020-02-27	Serum Inst Of India Pvt Ltd	An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof
JOP20190242A1 (ar)	2018-10-12	2020-04-12	Serum Institute Of India Pvt Ltd	تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
EP3972637A4 (en)	2019-05-20	2023-06-21	Soligenix, Inc.	COMPOSITIONS AND METHODS OF MANUFACTURE OF TRIVAL FILOVIRUS VACCINES
CN111658617A (zh) *	2019-10-14	2020-09-15	四川大学	一种含铝佐剂疫苗的冻干制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235877A (en)	1979-06-27	1980-11-25	Merck & Co., Inc.	Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en)	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en)	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4695624A (en)	1984-05-10	1987-09-22	Merck & Co., Inc.	Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IL98715A0 (en) *	1990-08-13	1992-07-15	American Cyanamid Co	Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
US5153312A (en)	1990-09-28	1992-10-06	American Cyanamid Company	Oligosaccharide conjugate vaccines
AU685047B2 (en)	1992-02-11	1998-01-15	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Dual carrier immunogenic construct
SK280702B6 (sk)	1992-05-23	2000-06-12	Smithkline Beecham Biologicals S. A.	Kombinovaný očkovací prostriedok obsahujúci povrch
DK0594950T3 (da) *	1992-10-27	1999-09-13	American Cyanamid Co	Pædiatrisk kombinationsvaccine med forbedret immunogenicitet af hver vaccinekomponent
ATE433329T1 (de) *	1995-06-23	2009-06-15	Glaxosmithkline Biolog Sa	Impfstoff bestehend aus auf aluminium-phosphat adsorbiertem, konjugiertem polysaccharid antigen

1996
- 1996-06-19 AT AT00203874T patent/ATE433329T1/de active
- 1996-06-19 SI SI9630310T patent/SI0833662T2/sl unknown
- 1996-06-19 HU HU9900061A patent/HU224514B1/hu active IP Right Grant
- 1996-06-19 EP EP96922871A patent/EP0833662B2/en not_active Expired - Lifetime
- 1996-06-19 CA CA2222455A patent/CA2222455C/en not_active Expired - Lifetime
- 1996-06-19 DK DK96922871.7T patent/DK0833662T4/da active
- 1996-06-19 AP APAP/P/1997/001159A patent/AP812A/en active
- 1996-06-19 CN CNB961949732A patent/CN1146444C/zh not_active Expired - Lifetime
- 1996-06-19 SI SI9630768T patent/SI1082965T1/sl unknown
- 1996-06-19 AT AT96922871T patent/ATE199831T1/de active
- 1996-06-19 PL PL96324242A patent/PL184872B1/pl unknown
- 1996-06-19 DE DE69612198T patent/DE69612198T3/de not_active Expired - Lifetime
- 1996-06-19 TR TR97/01682T patent/TR199701682T1/xx unknown
- 1996-06-19 CZ CZ19974189A patent/CZ288908B6/cs not_active IP Right Cessation
- 1996-06-19 ES ES00203874T patent/ES2325301T3/es not_active Expired - Lifetime
- 1996-06-19 JP JP50358197A patent/JP4850987B2/ja not_active Expired - Lifetime
- 1996-06-19 DK DK00203874T patent/DK1082965T3/da active
- 1996-06-19 NZ NZ312132A patent/NZ312132A/en not_active IP Right Cessation
- 1996-06-19 KR KR1019970709651A patent/KR100425929B1/ko not_active IP Right Cessation
- 1996-06-19 AU AU63591/96A patent/AU696338B2/en not_active Expired
- 1996-06-19 EP EP00203874A patent/EP1082965B1/en not_active Expired - Lifetime
- 1996-06-19 PT PT96922871T patent/PT833662E/pt unknown
- 1996-06-19 IL IL12258896A patent/IL122588A/en not_active IP Right Cessation
- 1996-06-19 DE DE69637950T patent/DE69637950D1/de not_active Expired - Lifetime
- 1996-06-19 EA EA199700413A patent/EA199700413A1/ru unknown
- 1996-06-19 BR BRPI9609414A patent/BRPI9609414B8/pt not_active IP Right Cessation
- 1996-06-19 SK SK1761-97A patent/SK176197A3/sk unknown
- 1996-06-19 ES ES96922871T patent/ES2157447T5/es not_active Expired - Lifetime
- 1996-06-19 PT PT00203874T patent/PT1082965E/pt unknown
- 1996-06-19 WO PCT/EP1996/002690 patent/WO1997000697A1/en active IP Right Grant
- 1996-06-21 PE PE1996000474A patent/PE11298A1/es not_active IP Right Cessation
- 1996-06-21 MY MYPI96002531A patent/MY114786A/en unknown
- 1996-06-21 MA MA24292A patent/MA23918A1/fr unknown
- 1996-06-21 AR ARP960103253A patent/AR003006A1/es active IP Right Grant
- 1996-06-22 DZ DZ960099A patent/DZ2055A1/fr active
- 1996-06-22 EG EG57496A patent/EG25924A/xx active
- 1996-06-25 TW TW085107646A patent/TW467746B/zh not_active IP Right Cessation
1997
- 1997-12-19 OA OA70169A patent/OA10646A/en unknown
- 1997-12-22 NO NO19976035A patent/NO325169B1/no not_active IP Right Cessation
- 1997-12-23 BG BG102146A patent/BG62720B1/bg unknown
1998
- 1998-09-23 HK HK01106309.2A patent/HK1037516A1/xx not_active IP Right Cessation
- 1998-09-23 HK HK98110884A patent/HK1009764A1/xx not_active IP Right Cessation
2001
- 2001-06-19 GR GR20010400933T patent/GR3036088T3/el unknown
2002
- 2002-09-23 CY CY0200056A patent/CY2297B1/xx unknown
2008
- 2008-02-14 JP JP2008033301A patent/JP2008120833A/ja active Pending

Also Published As

Publication number	Publication date
PE11298A1 (es)	1998-03-20
SI0833662T2 (sl)	2011-06-30
EP0833662B1 (en)	2001-03-21
PT833662E (pt)	2001-09-28
JP4850987B2 (ja)	2012-01-11
HU224514B1 (hu)	2005-10-28
CZ418997A3 (cs)	1998-06-17
NO976035L (no)	1998-02-16
BG62720B1 (bg)	2000-06-30
EP1082965A1 (en)	2001-03-14
OA10646A (en)	2002-09-18
HK1037516A1 (en)	2002-02-15
ES2157447T5 (es)	2011-04-29
AP9701159A0 (en)	1998-01-31
IL122588A (en)	2001-12-23
ES2157447T3 (es)	2001-08-16
HK1009764A1 (en)	1999-06-11
IL122588A0 (en)	1998-06-15
CN1146444C (zh)	2004-04-21
AP812A (en)	2000-02-24
DK1082965T3 (da)	2009-07-27
EP0833662B2 (en)	2011-01-26
HUP9900061A1 (hu)	1999-04-28
PT1082965E (pt)	2009-07-01
GR3036088T3 (en)	2001-09-28
NZ312132A (en)	1999-04-29
EA199700413A1 (ru)	1998-08-27
CN1188418A (zh)	1998-07-22
AR003006A1 (es)	1998-05-27
CA2222455A1 (en)	1997-01-09
ATE199831T1 (de)	2001-04-15
TW467746B (en)	2001-12-11
CY2297B1 (en)	2003-07-04
DE69637950D1 (de)	2009-07-23
AU6359196A (en)	1997-01-22
DK0833662T3 (da)	2001-07-09
PL184872B1 (pl)	2003-01-31
NO325169B1 (no)	2008-02-11
TR199701682T1 (xx)	1998-06-22
BR9609414B1 (pt)	2013-11-19
KR19990028336A (ko)	1999-04-15
MA23918A1 (fr)	1996-12-31
CZ288908B6 (cs)	2001-09-12
SI1082965T1 (sl)	2009-08-31
EP1082965B1 (en)	2009-06-10
DE69612198D1 (de)	2001-04-26
DZ2055A1 (fr)	2002-10-20
CA2222455C (en)	2013-05-28
BRPI9609414B8 (pt)	2021-05-25
AU696338B2 (en)	1998-09-10
NO976035D0 (no)	1997-12-22
MX9710521A (es)	1998-08-30
DE69612198T2 (de)	2001-11-08
ATE433329T1 (de)	2009-06-15
KR100425929B1 (ko)	2004-05-31
JPH11507935A (ja)	1999-07-13
DK0833662T4 (da)	2011-02-28
DE69612198T3 (de)	2011-08-18
BG102146A (en)	1998-10-30
MY114786A (en)	2003-01-31
JP2008120833A (ja)	2008-05-29
SK176197A3 (en)	1998-07-08
BR9609414A (pt)	1999-05-18
ES2325301T3 (es)	2009-09-01
EP0833662A1 (en)	1998-04-08
SI0833662T1 (en)	2001-12-31
HUP9900061A3 (en)	2000-03-28
PL324242A1 (en)	1998-05-11
WO1997000697A1 (en)	1997-01-09

Publication	Publication Date	Title
EG25924A (en)	2012-10-22	A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
ZA961460B (en)	1996-08-29	Vaccine compositions
GB9503240D0 (en)	1995-04-12	Preparation
AU3367395A (en)	1996-03-07	Water-soluble polyene conjugate
AU4415496A (en)	1996-08-07	Note or note pad preparation method
PL321686A1 (en)	1997-12-22	Trensdermal preparation
EP0815142A4 (en)	1999-07-14	ANTIGEN COMPOSITIONS AGAINST MYCOPLASMA
AU7716796A (en)	1997-06-19	Brake device
AU3154395A (en)	1996-03-04	Contraceptive vaccine
EP0967993A4 (en)	2001-04-18	ANTI-COCOA VACCINE
AU2769595A (en)	1996-01-15	Contraceptive vaccine
AU6820796A (en)	1997-03-12	Antigenic preparations
AP9801196A0 (en)	1998-03-31	Pharmaceutical preparation
GB9526433D0 (en)	1996-02-21	Vaccine component
ZA967542B (en)	1997-03-20	Pharmaceutical combination preparation comprising keto-profen
ZA965274B (en)	1997-05-27	A vaccine comprising a polysaccharide-antigen conjugate from haemophilus influenzae type b adsorbed onto aluminium phosphate and its use in combination vaccines
AU6371396A (en)	1997-02-05	Helicobacter antigens
AU6521996A (en)	1997-02-05	Preservative for a vaccine composition
AUPM447694A0 (en)	1994-04-14	Antigen composition
ZA964016B (en)	1996-12-02	Bacterial antigens and vaccine compositions
AUPN457395A0 (en)	1995-08-24	Tick antigen
AU4932496A (en)	1996-10-02	Antigen composition against mycoplasma
AU6826896A (en)	1997-03-19	Vaccines
GB9422344D0 (en)	1994-12-21	Antigens for immunisation
AUPM699694A0 (en)	1994-08-18	Tick antigen